Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
45 hedge funds and large institutions have $64.3M invested in Eiger BioPharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 3 closing their positions.
500% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 3
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
50% more funds holding
Funds holding: 30 → 45 (+15)
26% more capital invested
Capital invested by funds: $51.1M → $64.3M (+$13.2M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.84M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.76M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$683K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$438K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.55M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.71M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$251K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$68K |
| 5 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$24.3K |
EIGR Hedge Fund Activity: Q2 2016 in Review
45 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q2 2016, worth a combined $64.3M — up 26% from $51.1M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new EIGR positions and 3 closed out — a net gain of 15 holders — while 11 added to existing stakes and 6 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $2M. The largest seller was EcoR1 Capital, cutting an estimated $3.55M.
- 45 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q2 2016, up from 30 in Q1 2016.
- Funds reported $64.3M of Eiger BioPharmaceuticals, Inc. stock for Q2 2016, up 26% quarter-over-quarter.
- 18 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q2 2016 and 3 closed out, a net change of +15 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q2 2016 was Wellington Management Group, an estimated $2M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q2 2016 was EcoR1 Capital, an estimated $3.55M sold.
Based on aggregated 13F filings for Q2 2016.